From Triclosan toward the Clinic: Discovery of Nonbiocidal, Potent FabI Inhibitors for the Treatment of Resistant Bacteria
Journal of Medicinal Chemistry2012Vol. 55(22), pp. 9914–9928
Citations Over TimeTop 10% of 2012 papers
Vincent Gerusz, Alexis Denis, Fabien Faivre, Yannick Bonvin, Mayalen Oxoby, Sophia Briet, Géraldine LeFralliec, Chrystelle Oliveira, Nicolas Desroy, Cédric Raymond, Laëtitia Peltier, F. Moreau, Sonia Escaich, Vanida Vongsouthi, Stéphanie Floquet, Elodie Drocourt, Armelle Walton, Laure Prouvensier, Marc Saccomani, Lionel Durant, Jean-Marie Genevard, Vanessa Sam-Sambo, Coralie Soulama-Mouze
Abstract
In this paper, we present some elements of our optimization program to decouple triclosan's specific FabI effect from its nonspecific cytotoxic component. The implementation of this strategy delivered highly specific, potent, and nonbiocidal new FabI inhibitors. We also disclose some preclinical data of one of their representatives, 83, a novel antibacterial compound active against resistant staphylococci and some clinically relevant Gram negative bacteria that is currently undergoing clinical trials.
Related Papers
- Oral delivery and clearance of antiplaque agents from Triclosan-containing dentifrices.(1993)
- → Experiments With Triclosan-Containing Mouthrinses: Dose Response—and an Attempt to Locate the Receptor Site(S) of Triclosan in the Mouth(1994)9 cited
- Triclosan의 독성에 중금속이 미치는 영향 - V. fischeri Assay 관련 내용 중심으로 -(2014)
- Triclosan의 독성에 중금속이 미치는 영향(2014)
- → ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ(2024)